Product Information
CARBIDOPA-LEVO ER 50-200 TAB is a generic product labeled by ScieGen Pharmaceuticals Inc., priced at $0.1796 per EA under NDC 50228046110. Its NADAC has been published 191 times since Feb 8, 2023.
FDA first approved this application on Oct 5, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50; 200 mg/1; mg/1
Manufacturer
ScieGen Pharmaceuticals Inc.NDC
50228046110
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA214091FDA Approved
10/5/2021
TE Code
AB
On Market Since
10/5/2021
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVO ER 50-200 TAB has been published 191 times since Feb 8, 2023, and over the history we have for it it has declined 32.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1796 per EA |
|---|---|
| All-time high | $0.2884 (Aug 16, 2023) |
| All-time low | $0.1551 (May 22, 2024) |
| 52-week high | $0.2057 |
| 52-week low | $0.1676 |
| Median price | $0.2094 |
| Average price | $0.2118 |
| Largest weekly change | +52.4% (Jun 19, 2024) |
| Weeks tracked | 191 |
| Tracking since | Feb 8, 2023 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ScieGen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbidopa and Levodopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVO ER 50-200 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO ER 50-200 TAB, manufactured by ScieGen Pharmaceuticals Inc., is $0.1796 per EA (NDC 50228046110), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVO ER 50-200 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVO ER 50-200 TAB has declined 32.0%. It has been tracked across 191 weekly CMS publications since Feb 8, 2023.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO ER 50-200 TAB?
Since Feb 8, 2023, the NADAC for CARBIDOPA-LEVO ER 50-200 TAB has ranged from a low of $0.1551 (May 22, 2024) to a high of $0.2884 (Aug 16, 2023), with a median of $0.2094 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVO ER 50-200 TAB?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBIDOPA-LEVO ER 50-200 TAB, is $0.1735 per EA — about 3% below CARBIDOPA-LEVO ER 50-200 TAB.
Who manufactures CARBIDOPA-LEVO ER 50-200 TAB?
CARBIDOPA-LEVO ER 50-200 TAB (NDC 50228046110) is labeled by ScieGen Pharmaceuticals Inc., and CMS classifies it as a generic product.